- Home
- NCTY vs FATE Comparison
NCTY vs FATE Comparison
Compare NCTY & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- FATE
- Stock Information
- Founded
- NCTY 1999
- FATE 2007
- Country
- NCTY China
- FATE United States
- Employees
- NCTY N/A
- FATE N/A
- Industry
- NCTY Business Services
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCTY Consumer Discretionary
- FATE Health Care
- Exchange
- NCTY Nasdaq
- FATE Nasdaq
- Market Cap
- NCTY 156.7M
- FATE 133.0M
- IPO Year
- NCTY 2004
- FATE 2013
- Fundamental
- Price
- NCTY $9.36
- FATE $1.21
- Analyst Decision
- NCTY
- FATE Hold
- Analyst Count
- NCTY 0
- FATE 8
- Target Price
- NCTY N/A
- FATE $4.14
- AVG Volume (30 Days)
- NCTY 89.6K
- FATE 1.8M
- Earning Date
- NCTY 01-01-0001
- FATE 05-13-2025
- Dividend Yield
- NCTY N/A
- FATE N/A
- EPS Growth
- NCTY N/A
- FATE N/A
- EPS
- NCTY N/A
- FATE N/A
- Revenue
- NCTY $15,305,175.00
- FATE $13,335,000.00
- Revenue This Year
- NCTY N/A
- FATE N/A
- Revenue Next Year
- NCTY N/A
- FATE N/A
- P/E Ratio
- NCTY N/A
- FATE N/A
- Revenue Growth
- NCTY N/A
- FATE 105.85
- 52 Week Low
- NCTY $5.75
- FATE $0.66
- 52 Week High
- NCTY $20.59
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- NCTY 32.45
- FATE 53.44
- Support Level
- NCTY $11.21
- FATE $1.12
- Resistance Level
- NCTY $11.95
- FATE $1.38
- Average True Range (ATR)
- NCTY 0.75
- FATE 0.12
- MACD
- NCTY -0.21
- FATE 0.01
- Stochastic Oscillator
- NCTY 8.21
- FATE 62.22
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.